Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 42 min ago
Peer-reviewedCC BYExperimental biology and medicine (Maywood, N.J.)

Epigenetic reprogramming of NK cell-mediated antitumor immunity in urothelial carcinoma: a mini-review

  1. 1Department of Biomedical Sciences, National Chung Cheng University , ,
  2. 2Department of Urology, Ditmanson Medical Foundation Chiayi Christian Hospital , ,

Abstract

Urothelial carcinoma (UC) is a dynamic malignancy characterized by a complex epigenetic landscape. Epigenetic modifications are pivotal in modulating the innate immune response, particularly within the tumor microenvironment (TME), where they profoundly influence natural killer (NK) cell function. Aberrant epigenetic regulation often promotes immune evasion by silencing activating ligands on tumor cells, thereby impairing NK cell-mediated cytotoxicity. Emerging epigenetic therapies, such as histone deacetylase inhibitors (HDACis) and DNA methyltransferase inhibitors (DNMTis), offer significant potential to reprogram the immune landscape and restore anti-tumor immunity. Despite this promise, clinical implementation faces challenges, including the immunosuppressive nature of the TME, NK cell exhaustion, and complex manufacturing limitations. Combining epigenetic agents with NK cell-based immunotherapies represents a robust strategy to overcome these barriers and improve therapeutic outcomes. This review elucidates the epigenetic regulatory mechanisms in UC and emphasizes the necessity of personalized, biomarker-driven treatment strategies to optimize cancer immunotherapy outcomes.

Related

  1. 713 Vitamin B6-mediated lipid metabolic reprogramming as a strategy to restore antitumor T cell immunity in aging
    Nicola Vannini, Helen Carrasco Hope, Claudia Cifuentes Caballero +2
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textImmunologyDOAJ
  2. Gonadal remodelling in socially driven sex change is associated with novel and known sex genes, epigenetic reprogramming, and inflammation-mediated apoptosis.
    C. A. van der Burg, A. A. Goikoetxea, S. Muncaster +9
    bioRxivPreprintCC BYFull textGenetics & genomicsbioRxiv
  3. Ginseng-derived extracellular vesicles alleviate ulcerative colitis by regulating macrophage glycolytic reprogramming and H3K18la-mediated epigenetic modification
    Yuzhe Zhang, Ruipeng Li, Yuan Yang +6
    Journal of Ginseng ResearchPeer-reviewedCC BY-NC-NDFull textGenetics & genomicsDOAJEurope PMCPMC
  4. 455 Second primary malignancy risk in the immunotherapy era among urothelial carcinoma survivors: a SEER population-based analysis
    Jeffrey Afrifa-Yamoah, Damilola Ologbe, Duresha Malik +6
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYImmunologyOncologyDOAJ
  5. Transcriptional reprogramming and epigenetic regulation in Paramecium caudatum: a new model for studying extreme germline DNA elimination
    Yunyi Gao, Rui Wang, Yueer Yu +2
    Journal of genetics and genomics = Yi chuan xue baoPeer-reviewedLicence not statedFull textGenetics & genomicsPMC
BibTeX
@article{kumari2026epigenetic,
  title = {{Epigenetic reprogramming of NK cell-mediated antitumor immunity in urothelial carcinoma: a mini-review}},
  author = {Himani Kumari and Chih-Chieh Chou and Yu-Ting Lee and Cheng-Huang Shen and Michael W. Y. Chan},
  journal = {Experimental biology and medicine (Maywood, N.J.)},
  year = {2026},
  month = oct,
  doi = {10.3389/ebm.2026.11373},
  url = {https://europepmc.org/article/PMC/PMC13751542},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Epigenetic reprogramming of NK cell-mediated antitumor immunity in urothelial carcinoma: a mini-review
AU  - Himani Kumari
AU  - Chih-Chieh Chou
AU  - Yu-Ting Lee
AU  - Cheng-Huang Shen
AU  - Michael W. Y. Chan
PY  - 2026
DA  - 2026/10/28
JO  - Experimental biology and medicine (Maywood, N.J.)
DO  - 10.3389/ebm.2026.11373
UR  - https://europepmc.org/article/PMC/PMC13751542
AB  - Urothelial carcinoma (UC) is a dynamic malignancy characterized by a complex epigenetic landscape. Epigenetic modifications are pivotal in modulating the innate immune response, particularly within the tumor microenvironment (TME), where they profoundly influence natural killer (NK) cell function. Aberrant epigenetic regulation often promotes immune evasion by silencing activating ligands on tumor cells, thereby impairing NK cell-mediated cytotoxicity. Emerging epigenetic therapies, such as histone deacetylase inhibitors (HDACis) and DNA methyltransferase inhibitors (DNMTis), offer significant potential to reprogram the immune landscape and restore anti-tumor immunity. Despite this promise, clinical implementation faces challenges, including the immunosuppressive nature of the TME, NK cell exhaustion, and complex manufacturing limitations. Combining epigenetic agents with NK cell-based immunotherapies represents a robust strategy to overcome these barriers and improve therapeutic outcomes. This review elucidates the epigenetic regulatory mechanisms in UC and emphasizes the necessity of personalized, biomarker-driven treatment strategies to optimize cancer immunotherapy outcomes.
SN  - 1535-3702
SN  - 1535-3699
ER  -